AbbVie Inc. (NYSE:ABBV) is one of the best dividend aristocrat stocks to buy now. On June 19, AbbVie Inc. (NYSE:ABBV) ...
Researchers at the University of Eastern Finland and their international collaborators have identified key developmental and molecular differences between the two main subtypes of chronic lymphocytic ...
Eli Lilly and Company (NYSE:LLY) is one of the high growth stocks to buy right now. On June 14, Eli Lilly announced positive ...
There is no cure for chronic lymphocytic leukemia, but an array of new therapeutic strategies are improving outcomes for patients. The treatment of chronic lymphocytic leukemia (CLL) has evolved ...
MedPage Today on MSN
Triplet could become a new standard in tough-to-treat CLL
Adding a non-covalent BTK inhibitor improved progression-free survival ...
For (adult) patients with relapsed or refractory chronic lymphocytic leukemia (CLL), a new line of treatment has been ...
The National Institute for Health and Care Excellence (NICE) has issued draft guidance recommending a new oral treatment for people with relapsed or refractory chronic lymphocytic leukaemia (CLL). The ...
GlobalData on MSN
Lilly’s Jaypirca receives CHMP positive opinion for CLL in Europe
The Jaypirca application moves to the EC for a decision, expected within the next one to two months.
Researchers at the University of Eastern Finland and their international collaborators have identified key developmental and molecular differences between the two main subtypes of chronic lymphocytic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results